Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1093/annonc/mdz255.023 | A single arm, open label, phase II, multicenter study to assess the detection of the BRAF V600 mutation on cfDNA from plasma in patients with advanced melanoma |
| https://doi.org/10.1007/bf00421422 | Corrigendum notice |
| https://doi.org/10.1200/jco.2004.22.90140.733 | Effect of 1-year intravenous ibandronate treatment on time to serum creatinine increase in patients with skeletal metastases from breast cancer |
| https://doi.org/10.1002/uog.23183 | VP50.03: Economic evaluation of a new approach to first trimester screening, compared with the standard of care, to reduce pre‐eclampsia in Belgium |
| https://doi.org/10.1016/j.annonc.2022.07.1513 | 1381P A transcriptomic signature of AR activity prognosticates development of castration-resistance following metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer |
| https://doi.org/10.1186/s13071-022-05591-2 | Validation of a commercial version of a competitive enzyme linked immunosorbent assay for the detection of antibodies to Besnoitia besnoiti |
| https://doi.org/10.25144/16067 | INFLUENCE OF SHELLS AND SHELL DEBRIS ON BACKSCATTER STRENGTH INVESTIGATION USING MODELLING SONAR MEASUREMENTS & SAMPLING ON THE BELGIAN CONTINENTAL SHELF |
| https://doi.org/10.1200/jco.2024.42.16_suppl.e23184 | Understanding breast cancer (BC) from the patient (pt) perspective: A qualitative study of symptoms, impacts and health-related quality of life (HRQoL) in hormone receptor-positive, HER2-negative (HR+, HER2–) BC. |
| https://doi.org/10.1200/jco.2024.42.16_suppl.tps1130 | pionERA Breast Cancer (BC): Phase III study of first-line (1L) giredestrant vs. fulvestrant, both combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), in patients (pts) with estrogen receptor-positive (ER+), HER2– locally advanced/metastatic BC (LA/mBC) with resistance to prior adjuvant (adj) endocrine therapy (ET). |
| https://doi.org/10.1016/j.jval.2024.10.782 | EE501 Cost-Effectiveness Analysis (CEA) of Pertuzumab and Trastuzumab (PH) + Chemotherapy (CT) Versus H + CT in HER2-Positive Early Breast Cancer (EBC): Updated Model Using Data From the 8.4-Year Follow-up of APHINITY |
| https://doi.org/10.1016/j.jval.2024.10.1224 | EPH95 The Role of Adjuvant Atezolizumab in Reducing Recurrence-Related Treatment Costs in Resected Early-Stage PD-L1 High Non-Small Cell Lung Cancer in Belgium |
| https://doi.org/10.1016/j.jval.2025.09.097 | P58 An Evaluation Framework for Healthcare Professionals’ Digital Health and AI Technologies: Evidence-Based Policy Recommendations |
| https://doi.org/10.3390/engproc2026126009 | Inter-Satellite Link Network Real-Time Ring Dissemination Performance and Robustness |